(R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol → 9-fluoro-10-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-ynyl]-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide

HRID 575171

反応式

HRID 575171 の反応式
Br[C:2]1[C:3]([F:23])=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[C:12]([C:18]([NH:20][CH3:21])=[O:19])=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=[C:7]3[C:6]=2[CH:22]=1.[CH3:24][C:25]1[O:29][N:28]=[C:27]([C@:30]([OH:34])([C:32]#[CH:33])[CH3:31])[N:26]=1>>[F:23][C:3]1[C:2]([C:33]#[C:32][C@@:30]([OH:34])([C:27]2[N:26]=[C:25]([CH3:24])[O:29][N:28]=2)[CH3:31])=[CH:22][C:6]2[C:7]3[N:8]([C:12]([C:18]([NH:20][CH3:21])=[O:19])=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=3)[CH2:9][CH2:10][O:11][C:5]=2[CH:4]=1

参加物

3

反応物 2

HCID 86669593(R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-olHCID 8669318410-Bromo-9-fluoro-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide

生成物 1

HCID 866931859-fluoro-10-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-ynyl]-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide

実験手順

10-Bromo-9-fluoro-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide (0.08 g) was reacted with (2R)-2-(5-methyl-1,2,4-oxadiazol-3-yl)but-3-yn-2-ol similar to as described in Procedure E to afford 8.6 mg of 9-fluoro-10-[(3R)-3-hydroxy-3-(5-methyl-1,2,4-oxadiazol-3-yl)but-1-ynyl]-N3-methyl-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepine-2,3-dicarboxamide following reverse phase hplc purification. MS (Q1) 455 (M)+. 1H NMR (400 MHz, DMSO) δ 11.09 (q, J=4.4 Hz, 1H), 8.65 (d, J=8.3 Hz, 1H), 8.38 (s, 1H), 7.86 (s, 1H), 7.06 (d, J=10.5 Hz, 1H), 6.76 (s, 1H), 6.59 (s, 1H), 5.08-4.94 (m, 2H), 4.63-4.41 (m, 2H), 2.80 (d, J=4.5 Hz, 3H), 2.62 (s, 3H), 1.86 (s, 3H).

出典と根拠

ORDレコード
ord-7de1069019ea4bada433d59ecab55576
出典データセット
uspto-grants-2015_05
特許番号
US09034866B2

関連ノート

読み込み中…